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Intellectual property is a double edged sword, which can stimulate innovation. 
Meanwhile it also may provide the breeding ground for the abuse of rights to 
restrict free competition. The pharmaceutical industry is highly dependent on 
intellectual property rights. If the patent drug companies abuse their patents, it 
will put off the healthy development of the pharmaceutical industry. And it will 
postpone the time when the public can buy cheap generic drugs, affecting the 
public health and the welfare. Reverse payment is a common behavior under 
pharmaceutical patent litigation in the United States. By reverse payment 
agreements, patent drug companies can well achieve their purpose to postpone the 
time when the public can buy cheap generic drugs, which can make patent drug 
companies gain a lot of monopoly profits. Recently, a large number of 
pharmaceutical patents will expiry in China. In order to maintain the huge 
monopoly profits, drug companies will delay generic drugs listed in various ways . 
The reverse payment is the most effective way to delay, so the reverse payment 
agreements will appear inevitably in our country. Different purpose, contents, and 
formats of the reverse payment agreements will lead to different results. 
American judiciary applies the principle of reasonableness, the per se rule, a 
quick review of the principles and rules on the scope of patent test to judge 
reverse payment under antitrust mechanism. This paper studies on the American 
judiciary to know how to apply antitrust principles and approaches about the 
reverse payments, and to analyze the latest jurisprudence, seeking the best ideas 
to solve this problem. Provide recommendations for improvement and to prevent 
the abuse of intellectual property rights within pharmaceutical patent system of 















This article is composed of introduction, text and conclusion, the main text is 
divided into three chapters. 
 
Chapter 1 analyzes the generated background of pharmaceutical reverse payments. 
It mainly analyzes from three angles. They are industry backgrounds, social 
backgrounds and legal backgrounds. Chapter 2 discusses the American judicial 
practice about the principles and methods of antitrust issues adapt to 
pharmaceutical reverse payments. It also researches on the U.S. Federal Supreme 
Court ruling of a drug patent antitrust case ----FTC. V. Actavis, Inc. Case, which 
was sentenced on June 17, 2013. This case is on behalf of the latest and most 
in-depth discussion of the American legal profession. Chapter 3 analyzes the 
status situation of China's pharmaceutical patent system, drawing on the 
experience of U.S. intellectual property and antitrust regulation, in order to 
provide suggestions for China to deal with reverse payment regulations. 
 















英文缩写 英文全称 中文全称 
FTC Federal Trade Commission 美国联邦贸易委员会 
FDA Food and Drug Administration 美国联邦食品药品署 
NDA New Drug Application 新药申请 
ANDA Abbreviated New Drug Application 简略新药申请 
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① 2012 年品牌药将会直面专利“悬崖”[N] . 医药经济报, 2011-9-20(1). 





























本。新药研发创新至少需要 10 年，花费 10 亿美元以上，这是医药行业对
新药研发所需要耗费的时间和财力普遍流传的看法。《福布斯》杂志在对







                                                 



























度过程中，不断追求的目标。早在 20 世纪 60 年代，美国联邦食品药品署(Food 







专利药。2004 美国一款专利药的平均售价是 96 美元，而含相同活性成分的
仿制药的平均售价仅为 29 美元。②为保持市场竞争优势，攫取高额垄断利润，
专利药行业对其专利药物设置了重重专利保护。所以，仿制药行业要想发
                                                 
① 陈武.美国药品专利诉讼中的反向支付协议——以 Cardizem CD 及 ValleyDrug 案为研究进路[J]. 世界知识
产权, 2007,(4):82-87. 
② U.S. CENSUS BUREAU. Statistical Abstract of the United States: 2006, Section3 Health & Nutrition[EB/OL], 
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